TDMS Study 88133-06 Pathology Tables
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
Final#2
Facility: Battelle Columbus Laboratory
Chemical CAS #: 15625-89-5
Lock Date: 06/16/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 002 0 MG/KG
Include 001 0 MG/KG
Include 004 0.75 MG/KG
Include 003 0.75 MG/KG
Include 006 1.5 MG/KG
Include 005 1.5 MG/KG
Include 008 3 MG/KG
Include 007 3 MG/KG
Include 010 6 MG/KG
Include 009 6 MG/KG
Include 012 12 MG/KG
Include 011 12 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 2 1 1 3
Moribund Sacrifice 1
Survivors
Terminal Sacrifice 15 14 12 14 14 12
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 [2.0] 6 [1.8]
Infiltration Cellular 1 [2.0] 1 [2.0]
Inflammation, Chronic Active 15 [1.1] 14 [1.1] 13 [1.2] 13 [1.0] 14 [1.0] 8 [1.3]
Myelodysplasia 2 [2.5]
Pigmentation 12 [1.0] 15 [1.1] 12 [1.0] 13 [1.0] 14 [1.0] 4 [1.0]
Hepatocyte, Necrosis 4 [1.3] 2 [1.0] 1 [1.0] 2 [1.0] 1 [1.0] 1 [1.0]
Salivary Glands (1) (1)
Parotid Gland, Infiltration Cellular 1 [1.0]
Tooth (1) (4) (3) (1) (3) (2)
Fibrosis 1 [4.0]
Inflammation, Chronic Active 1 [4.0]
Malformation 1
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 [1.0]
Atrium, Thrombosis 1 [4.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Pituitary Gland (15) (15) (15) (15) (15) (15)
Pars Distalis, Angiectasis 1 [1.0]
Pars Distalis, Cyst 1 [1.0] 2 [1.0] 1 [1.0] 2 [1.5] 2 [1.0]
Thyroid Gland (15) (15) (15) (15) (15) (15)
Infiltration Cellular 1 [2.0]
Inflammation, Chronic Active 2 [1.5]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (15) (15)
Cyst 1 [2.0] 1 [2.0] 1 [2.0]
Inflammation, Chronic Active 1 [2.0] 1 [2.0]
Pigmentation 1 [2.0] 1 [2.0]
Uterus (15) (15) (15) (15) (15) (15)
Hydrometra 1 [2.0] 1 [2.0] 1 [4.0] 1 [2.0]
Inflammation, Chronic Active 1 [2.0]
Cervix, Inflammation, Chronic Active 1 [2.0]
Endometrium, Hyperplasia, Cystic 10 [1.6] 11 [1.6] 7 [1.4] 8 [1.8] 8 [1.8] 9 [1.7]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (11) (14) (13) (10) (13) (12)
Hematopoietic Cell Proliferation 2 [3.0]
Hyperplasia 2 [3.5]
Inguinal, Hematopoietic Cell Proliferation 1 [2.0]
Inguinal, Hyperplasia 1 [2.0]
Inguinal, Infiltration Cellular, Plasma Cell 2 [3.0]
Inguinal, Myelodysplasia 2 [2.5]
Mediastinal, Hematopoietic Cell Proliferation 5 [2.0]
Mediastinal, Infiltration Cellular 1 [2.0] 2 [2.0]
Mediastinal, Infiltration Cellular, Plasma
Cell 2 [2.0]
Lymph Node, Mandibular (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 [3.0] 6 [2.0]
Hyperplasia 1 [2.0] 3 [3.3] 2 [2.5] 2 [3.0] 3 [2.0]
Hyperplasia, Plasma Cell 1 [2.0] 1 [4.0]
Infiltration Cellular 1 [3.0] 1 [3.0]
Infiltration Cellular, Plasma Cell 1 [3.0] 2 [2.5]
Inflammation, Chronic Active 1 [3.0]
Myelodysplasia 1 [3.0]
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (15)
Hematopoietic Cell Proliferation 4 [2.0]
Infiltration Cellular 2 [2.5]
Spleen (15) (15) (15) (15) (15) (15)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Atrophy 1 [1.0] 3 [2.3] 1 [2.0] 2 [2.0] 1 [3.0]
Hematopoietic Cell Proliferation 7 [1.1] 13 [1.8] 9 [1.6] 6 [1.8] 8 [1.8] 10 [2.7]
Hyperplasia, Lymphoid 2 [1.0] 2 [2.0] 2 [3.5]
Infiltration Cellular 1 [1.0]
Myelodysplasia 2 [2.0]
Thymus (15) (15) (15) (15) (15) (15)
Atrophy 1 [4.0] 3 [3.3] 2 [3.0] 2 [3.5] 3 [3.7]
Thymocyte, Necrosis 2 [3.0] 1 [4.0] 1 [3.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Epidermis, Skin, Site of Application,
Hyperplasia 1 [2.0] 4 [1.0] 15 [1.2] 15 [2.0]
Epidermis, Skin, Site of Application,
Hyperplasia, Focal 1 [4.0] 1 [3.0] 8 [2.8]
Skin, Site of Application, Hyperkeratosis 1 [1.0] 7 [1.0] 14 [1.1] 13 [1.6]
Skin, Site of Application, Hyperplasia 1 [1.0]
Skin, Site of Application, Inflammation,
Chronic Active 3 [1.0] 14 [1.0] 12 [1.3]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 [1.0]
Mediastinum, Infiltration Cellular 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 2 [1.0] 3 [1.0]
Mineralization 1 [1.0]
Nephropathy 4 [1.0] 1 [1.0]
Renal Tubule, Cyst 1 [2.0]
Renal Tubule, Regeneration 1 [1.0] 2 [1.0] 1 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 3 1 2 4
Survivors
Terminal Sacrifice 14 15 12 14 13 11
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Basophilic Focus 1
Hematopoietic Cell Proliferation 1 [1.0] 1 [1.0] 6 [1.3]
Infarct 1 [4.0]
Infiltration Cellular 5 [1.6]
Inflammation, Acute 1 [1.0]
Inflammation, Chronic Active 7 [1.1] 10 [1.0] 8 [1.0] 8 [1.0] 7 [1.0] 8 [1.3]
Mineralization 1 [1.0]
Myelodysplasia 1 [1.0]
Pigmentation 2 [1.0]
Hepatocyte, Necrosis 2 [1.5] 2 [1.0] 2 [1.0] 1 [1.0] 1 [2.0]
Mesentery (1) (1)
Fat, Necrosis 1 [4.0] 1 [4.0]
Salivary Glands (1) (1) (2)
Mandibular, Infiltration Cellular 1 [1.0]
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Hyperkeratosis 1 [2.0] 1 [2.0] 3 [2.0]
Inflammation, Chronic Active 1 [3.0]
Epithelium, Hyperplasia 1 [4.0]
Tooth (1) (3) (1) (2) (1) (1)
Inflammation, Chronic Active 1 [3.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Atrium, Thrombosis 1 [4.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Adrenal Cortex (15) (15) (15) (15) (15) (15)
Hyperplasia 1 [1.0]
Hypertrophy 7 [1.6] 5 [1.8] 9 [1.7] 8 [1.3] 5 [1.4] 5 [1.4]
Vacuolization Cytoplasmic 1 [1.0]
Pituitary Gland (15) (15) (15) (14) (15) (15)
Pars Distalis, Cyst 2 [1.0] 1 [1.0] 1 [2.0] 1 [1.0] 1 [1.0] 2 [1.0]
Thyroid Gland (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 [1.0]
Follicle, Cyst 1 [2.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (15) (15) (15) (15) (15) (15)
Atrophy 1 [2.0]
Inflammation, Chronic Active 2 [1.5] 3 [2.3]
Myelodysplasia 1 [3.0]
Bilateral, Hypospermia 1 [4.0]
Unilateral, Hypospermia 4 [3.8] 3 [4.0] 1 [4.0] 1 [4.0] 2 [4.0]
Preputial Gland (1) (1)
Inflammation, Chronic Active 1 [3.0]
Duct, Ectasia 1 [2.0]
Testes (15) (15) (15) (15) (15) (15)
Cyst 2 [2.0] 1 [2.0] 1 [2.0]
Bilateral, Germinal Epithelium, Degeneration 1 [4.0]
Germinal Epithelium, Degeneration 1 [1.0]
Unilateral, Germinal Epithelium, Degeneration 4 [2.5] 3 [2.7] 1 [2.0] 1 [2.0] 2 [2.5]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (13) (13) (14) (15) (14) (14)
Hyperplasia 4 [3.5]
Inflammation, Chronic Active 3 [2.3]
Axillary, Infiltration Cellular 1 [3.0]
Axillary, Infiltration Cellular, Plasma Cell 1 [3.0]
Inguinal, Hyperplasia 1 [4.0]
Inguinal, Inflammation, Chronic Active 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Mediastinal, Hematopoietic Cell Proliferation 1 [2.0]
Mediastinal, Hyperplasia 1 [2.0]
Mediastinal, Infiltration Cellular 3 [2.3]
Mediastinal, Infiltration Cellular, Plasma
Cell 3 [2.3]
Mediastinal, Inflammation, Chronic Active 2 [2.0]
Lymph Node, Mandibular (15) (14) (15) (15) (14) (13)
Hematopoietic Cell Proliferation 2 [1.5]
Hyperplasia 1 [2.0] 1 [2.0]
Hyperplasia, Plasma Cell 1 [3.0] 1 [2.0]
Infiltration Cellular 4 [1.8]
Infiltration Cellular, Plasma Cell 1 [2.0]
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (12)
Infiltration Cellular 1 [1.0]
Spleen (15) (15) (15) (15) (15) (15)
Atrophy 1 [2.0] 1 [1.0] 4 [1.8]
Depletion Cellular 1 [3.0] 1 [2.0]
Hematopoietic Cell Proliferation 1 [2.0] 4 [1.5] 1 [3.0] 2 [1.5] 6 [2.0] 8 [2.6]
Hyperplasia, Lymphoid 1 [1.0] 1 [4.0] 1 [1.0] 1 [1.0]
Thymus (15) (15) (14) (15) (15) (15)
Atrophy 1 [2.0] 1 [4.0] 2 [3.5] 5 [3.0]
Thymocyte, Necrosis 1 [2.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Epidermis, Skin, Site of Application,
Hyperplasia 6 [1.0] 14 [1.7] 15 [1.9]
Epidermis, Skin, Site of Application,
Hyperplasia, Focal 1 [4.0] 1 [4.0]
Skin, Site of Application, Hyperkeratosis 1 [2.0] 15 [1.0] 14 [1.1] 12 [1.7]
Skin, Site of Application, Hyperplasia 1 [3.0]
Skin, Site of Application, Inflammation,
Chronic Active 1 [1.0] 1 [1.0] 9 [1.1] 12 [1.3]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Time: 08:54:16
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (14)
Inflammation, Chronic Active 2 [1.0] 2 [1.5]
Thrombosis 1 [4.0]
Interstitium, Hyperplasia 1 [1.0]
Interstitium, Inflammation, Chronic Active 1 [3.0]
Mediastinum, Infiltration Cellular 1 [1.0]
Mediastinum, Inflammation, Chronic Active 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Infarct 1 [3.0] 1 [2.0]
Infiltration Cellular 1 [1.0]
Infiltration Cellular, Mononuclear Cell 1 [1.0] 1 [1.0] 1 [1.0]
Inflammation, Chronic Active 2 [1.0] 1 [1.0] 1 [1.0] 5 [1.2]
Mineralization 1 [1.0]
Nephropathy 3 [1.0] 6 [1.0] 3 [1.0]
Glomerulus, Renal Tubule, Dilatation 1 [2.0]
Renal Tubule, Cyst 1 [2.0] 1 [2.0] 1 [1.0]
Renal Tubule, Hyperplasia 1 [1.0] 1 [1.0] 1 [2.0] 1 [2.0]
Renal Tubule, Regeneration 2 [1.0] 1 [1.0] 5 [1.0] 4 [1.0] 4 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------